Background Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic used to treat many significant infections due to its high antibacterial potential, a broad spectrum of activity, and low toxicity. These antibiotics are prescribed for various infections every day, especially in developing countries. The difference in the price of generic and brand-name ceftriaxone impressed that brand-name drug has better quality than generic. This study aimed to compare brand-name ceftriaxone's quality over generics that have a notable price difference. Methods: We presumed all ceftriaxone injections had a similar quality. Escherichia coli ATCC? 25922 with MIC of 0.03-0.12 ug/ml against ceftriaxone was used as the evaluation standard. Using Mueller Hinton agar with serial ceftriaxone concentration double diluted from 0.48 until 0.0075 ug/ml. There were three groups of ceftriaxone, brand-name, generic name, and control (SIGMA Aldrich). A drop of suspension of Escherichia coli ATCC-25922 in 20 ?l of 104CFU was applied on the surface medium. After incubation at 37?C overnight, the MIC of the three groups was noted. MIC, as shown in the concentration of 0.03-0.12 ug/ml, was confirmed as good quality ceftriaxone. Results A total of 11 brand names and 14 generic ceftriaxone injections shared identical MIC at 0.06 ?g/ml. Brand-name ceftriaxone overpriced generic with average price 234,400 ($16,32) and 16,686 ($1,16) respectively. Conclusion: While being sold at a higher price, brand-name ceftriaxone has equivalent in vitro potency to generic.